We remain positive about financial performance for Bioalpha in FY 2017. Forecasted total sales amount will be increased to RM65m in FY2017 as compared against FY2016 at RM48m. We make a very conservative estimation about the net profit will be around RM11m in FY2017 as compared to RM8m in FY2016.

We strong believed financial performance will be strong recover in coming Q2 result based on the factor as follows:

1. 11 new product in its 3 main market of Indonesia, China & Malaysia will be launched in 1H17, to push up the sales especially in Indonesia market. Previously, Indonesia market is doing very well, plus the new plant is start to operate which will further lower down the shipment cost to this main market.

2. Expect higher sales from China market, with the Halal certificate. We understand that in market there is very less of supplement with come with Halal certificate. This is the main bullet for Bioalpha to target the bigger muslim market and the competition is much lower.

3. Official launch of e-constant. How effective of this webpage sales we still unable to determine. Hope it will be another shopping website like Lazada.

4. More franchise for pharmacies will be open during this year to push up their product. Target will be the next something like Caring.

So, what is the concern now? Please buy and keep for future to reward you once the company activities all is take place.